Abstract
Background:
Ankylosing spondylitis (AS) is a complex condition with a significant genetic component. This study explored circulating proteins as potential genetic drug targets or biomarkers to prevent AS, addressing the need for innovative and safe treatments.
Methods:
We analyzed extensive data from protein quantitative trait loci (pQTLs) with up to 1,949 instrumental variables (IVs) and selected the top single-nucleotide polymorphism (SNP) associated with AS risk. Utilizing a two-sample Mendelian randomization (MR) approach, we assessed the causal relationships between identified proteins and AS risk. Colocalization analysis, functional enrichment, and construction of protein-protein interaction networks further supported these findings. We utilized phenome-wide MR (phenMR) analysis for broader validation and repurposing of drugs targeting these proteins. The Drug-Gene Interaction database (DGIdb) was employed to corroborate drug associations with potential therapeutic targets. Additionally, molecular docking (MD) techniques were applied to evaluate the interaction between target protein and four potential AS drugs identified from the DGIdb.
Results:
Our analysis identified 1,654 plasma proteins linked to AS, with 868 up-regulated and 786 down-regulated. 18 proteins (AGER, AIF1, ATF6B, C4A, CFB, CLIC1, COL11A2, ERAP1, HLA-DQA2, HSPA1L, IL23R, LILRB3, MAPK14, MICA, MICB, MPIG6B, TNXB, and VARS1) that show promise as therapeutic targets for AS or biomarkers, especially MAPK14, supported by evidence of colocalization. PhenMR analysis linked these proteins to AS and other diseases, while DGIdb analysis identified potential drugs related to MAPK14. MD analysis indicated strong binding affinities between MAPK14 and four potential AS drugs, suggesting effective target-drug interactions.
Conclusion:
This study underscores the utility of MR analysis in AS research for identifying biomarkers and therapeutic drug targets. The involvement of Th17 cell differentiation-related proteins in AS pathogenesis is particularly notable. Clinical validation and further investigation are essential for future applications.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory joint disease that exhibits significant regional and population-based variations in prevalence, influenced primarily by genetic predisposition, shaping both disease susceptibility and severity (). It commonly appears during adolescence or early adulthood and is more prevalent in men. The disease is notably associated with genetic factors, including the presence of the HLA-B27 antigen, and its prevalence varies significantly across different regions and populations ().
In recent years, pharmaceutical research has made substantial progress, introducing new therapeutic options alongside conventional treatments such as non-steroidal anti-inflammatory drugs (NSAIDs) and biologic disease-modifying antirheumatic drugs (bDMARDs) (). Notably, FDA-approved medications like tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) have significantly enhanced the quality of life for those with AS (). Despite these advancements, the quest for more effective treatments continues, especially for patients who do not respond adequately to existing therapies.
Pharmaceuticals often target specific proteins, and genetic variations affecting protein expression provide opportunities for drug repurposing and the development of new treatments (). This study focuses on the potential of proteomic technologies to identify new therapeutic targets. Proteins, due to their diverse functions, serve as excellent candidates for uncovering disease biomarkers and therapeutic targets (). Advances in genetic and proteomic analysis, such as Mendelian Randomization (MR) and Genome-wide Association Studies (GWAS), have facilitated the use of large-scale data to establish causality between genetic variations and disease, simulating the effects of randomized clinical trials. This approach helps minimize the influence of confounding factors and enhances the prediction of individual responses to treatment, thus supporting personalized medicine (, ). Despite the potential, the genomic basis for new drug targets in AS has remained largely unexplored. MR analysis of the drug target gene is a statistical approach used to evaluate whether a particular gene is associated with the therapeutic effects of a drug (). It offers advantages over traditional research methods, using genetic variations to simulate randomized clinical trials, thus providing stronger causal evidence, reducing the impact of confounding variables, supporting high-throughput screening, saving time and resources, and advancing personalized medicine (). This aids to gain a deeper understanding of the mechanism of action of the drug and enhances the prediction of individual responses to the drug. To our knowledge, the genomic evidence for potential drug targets in AS remains unexplored.
We used a genetic instrument comprising 1,949 circulating plasma proteins from extensive proteomics research. We obtained AS data from publicly available datasets. Using MR and colocalization analysis within the proteomic realm, we investigated the causal links between circulatory proteins and AS, identifying potential therapeutic targets. We also evaluated protein-protein interactions (PPI) and suitability for drug development, prioritizing treatment targets and biomarkers. This research sheds light on the causal associations between proteins and AS, offering new insights and therapeutic possibilities. Our findings contribute to a deeper understanding of AS and provide a foundation for the development of targeted therapies, representing a significant advancement in the treatment and prevention of this debilitating disease.
Materials and methods
Screening instrumental variables and data sources
In this study, genetic variants associated with protein abundance are differentiated into cis-acting and trans-acting types. The quantitative trait loci that act on CS (pQTLs) were typically located near the genes that encode the corresponding proteins (within 1Mb in this work) and have direct and independent biological effects (). Proteins are more likely than other molecular traits to be used as drug targets, and MR analysis combined with pQTL as instrumental variables (IVs) is valuable for drug development in human genetics. We integrated the cis-pQTL data derived from prior studies conducted by Sun BB etĀ al. (ā) as our genetic IVs source. Significance thresholds were set at P< 5e-8 (with a minor allele frequency > 0.01) and a linkage disequilibrium (LD) threshold of R2< 0.8, kb = 10,000, utilizing the two-sample MR package (version 0.5.7) R (). The explanatory power of IVs concerning exposure was quantified using the F-statistic as shown below:
In this formula, MAF represents the minimum allele frequency; β represents the effect size in GWAS for proteins and sd is its standard deviation (sd = se à ); N is the total number of samples in the proteins GWAS; k is the number of IVs used (). An F-statistic below 10 suggests a potentially weak IV strength, indicative of inadequate suitability for robust causal inference. Blood pQTLs associated with AS were identified from the latest public GWAS database as outcomes (https://storage.googleapis.com/finngen-public-data-r9/summary_stats/finngen_R9_M13_ANKYLOSPON.gz). We employed blood proteomic profiling data as SNPs to perform a two-sample MR analysis across two independent cohorts consisting of 2,860 AS cases and 270,964 controls. This methodological approach facilitates the identification of SNPs linked to specific protein expressions, advancing research into genetic variations associated with diseases. The workflow of the study is depicted in Figure 1.
FigureĀ 1
MR and statistical analysis
MR analysis mandates the fulfillment of three crucial assumptions: genetic instruments are strongly correlated with exposure, genetic instruments are independent of confounding factors, and genetic instruments solely influence the outcome through their impact on exposure. The Wald ratio (WR) method was employed for preliminary explorations of the top SNPs. (most significant SNPs) (, ). Where only a single IV was available with a P-value of<1e-05, the WR was computed. A Bonferroni correction was applied to the P-value (0.05/1,654 = 0.00003023) to mitigate the false discovery rate (FDR), and findings were articulated using statistical metrics (Odds Ratio and 95% Confidence Interval) (). Throughout these analyses, only results with a statistically significant level (P< 0.05) were retained to ensure the reliability of the results.
Colocalization analysis
Colocalization analysis serves as a methodological approach for investigating protein-protein interactions and functions (). When comparing the subcellular localization patterns of proteins, we reveal their interrelationships. This analysis facilitates the assessment of whether disease-associated and genetic regulation of protein levels are driven by identical genetic variants. In our study, we used Bayesian colocalization analysis with default parameters from the ācolocā software package to assess the likelihood of two features sharing the same causal variation (). We evaluated five hypothesesā posterior probabilities (PPH) to ascertain whether two features are influenced by a common variant. The coloc.abf algorithm was applied, classifying proteins as first-tier (PPH4 > 0.8) with strong evidence of colocalization, second-tier (0.5< PPH4< 0.8) with moderate support, and others as third-tier targets based on prior research ().
Proteināprotein interaction network and GO/KEGG analysis
The exploration of protein-protein interactions (PPI) was facilitated using the String database (https://string-db.org/) (). It contains known protein interaction data from various sources, including experimental evidence and computational predictions. This step involved data preparation, access to the String database, extraction of the PPI network, and subsequent visualization and analytical interpretation of these interactions. The parameters for this study were configured as follows: the network edges were specifically interpreted as indicators of interaction evidence, while the active interaction sources included a range of methodologies such as textmining, experimental assays, Database entries, co-expression patterns, proximity in genomic context, Gene Fusion events, and co-occurrence statistics. The threshold for inclusion in the network was set at a medium confidence score of 0.400 to ensure relevance and reliability of the interactions.
Regarding the identification of candidate genes implicated in AS pathogenesis, genes derived from the Bonferroni correction statistical approach were pinpointed as key targets. Further insights into the biological pathways and functional attributions of these genes were gleaned through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. These analyses were performed using Metascape (http://metascape.org) and the Oebiotech platform (https://cloud.oebiotech.cn/, last accessed on 12 January 2024) (). These tools facilitated the visualization and interpretation of potential pathways involved in the diseaseās progression and pathogenesis, enhancing our understanding of the molecular mechanisms at play (, ).
Phenome-wide MR analysis
Phenome-wide mendelian randomization (PhenMR), integrating principles from both Mendelian Randomization (MR) and Phenome-Wide Association Studies (PheWAS), is employed to elucidate the causal relationships between genes and a spectrum of phenotypic traits (). This method enables a broad assessment of genetic impacts across health and disease phenotypes, revealing gene-phenotype associations and facilitating the exploration of genetic functions and biological underpinnings.
To exclude potential pleiotropy of AS, we performed a PheWAS analysis using variants identified from the GWAS ATLAS and Pheno-Scanner databases (ā). This analysis allows for the investigation of how the six primary proteins linked to AS are associated with various traits, shedding light on their roles in AS pathogenesis and their potential as therapeutic targets.
Drugs investigation: DGIdb analysis
The drug gene interaction database (DGIdb) (https://dgidb.genome.wustl.edu) is a database that integrates drug-gene interaction data from 30 existing databases, helping researchers to explore existing data to generate hypotheses about how genes can be used in therapy or drug development (). It allows users to search for drugs that target specific genes of interest, including FDA-approved, experimental, and investigational drugs, along with information on their indications, target genes, and interaction types. Our search within the DGIdb was guided by prior research, focusing on genes associated with potential treatment modalities for AS (). Ethical approval had been obtained from their institutional review board in each study, and all participants had provided informed consent, obviating the need for additional ethical approval.
Molecular docking analysis of MAPK14 with selected pharmacological agents
The three-dimensional configuration of the MAPK14 protein was sourced from the Protein Data Bank (https://www1.rcsb.org, PDB ID: 6zwp) and refined by removing non-essential entities using PyMOL software, version 2.5.4 (, ). The molecular structures of four therapeutic agents, as identified in the Drug Gene Interaction Database (DGIdb), along with a co-crystallized ligand, were retrieved from the PubChem repository, (https://pubchem.ncbi.nlm.nih.gov) and subjected to structural optimization employing OpenBabel (version 3.1.1) and ORCA (version 5.03) (ā). The root mean square deviation (RMSD) values for co-crystallized ligand structures were calculated before and after docking using PyMOL software. An RMSD value of less than 2 Ć indicates successful methodological validation. Computational assessments were conducted using the B3LYP hybrid functional combined with the def2-TZVP basis set. To prepare for molecular docking, modifications to enhance hydrogen bonding and molecular flexibility were executed using Auto Dock Tools version 1.5.6. The docking procedure itself was facilitated by Autodock Vina software (version 1.2.0), employing the Lamarckian genetic algorithm to optimize interaction predictions (). Specific parameters for the docking grid were set with a central point at coordinates (X, Y, Z) = (6, 0, 19) and dimensions spanning (XĆYĆZ) = (26Ć26Ć24), with an exhaustiveness setting of 25 to ensure thorough sampling.
Results
Identifying plasma proteins related to AS
This study explored how certain proteins, for which genetic markers are known, are related to the risk of AS. We focused on 1,949 proteins that have identifiable genetic signals known as pQTLs and examined their influence on the development and severity of AS. FigureĀ 2 provides a summary of these findings. We match a single cis-SNP for each protein by integrating genetic data from pQTL, and we identify 1,654 unique circulating plasma proteins that met the criteria for having a causal relationship with AS (Supplementary Table S1). Among these, 868 proteins showed a positive causal relationship with AS, while 786 proteins showed a negative causal relationship with AS. This suggested that specific genetic variations may be associated with the risk of AS by influencing the expression or function of these plasma proteins, thus affecting the occurrence of AS.
FigureĀ 2
Exploring causal plasma proteins on AS
To ensure the reliability of our findings, we used the Bonferroni correction method to adjust for multiple comparisons, setting a strict significance threshold (P value = 0.05/1,654, P< 3.03E-05). Among the 1,654 plasma proteins mentioned above, we identified 18 that were significantly associated with the risk of developing AS. These proteins included AGER, AIF1, ATF6B, C4A, CFB, CLIC1, COL11A2, ERAP1, HLA-DQA2, HSPA1L, IL23R, LILRB3, MAPK14, MICA, MICB, MPIG6B, TNXB and VARS1. Specifically, seven of these proteins were associated with an increased risk of AS, including ATF6B, C4A, COL11A2, etc. Additionally, 11 proteins were found to lower the risk of AS, such as AIF1, MAPK14, MICA, MICB, etc. Interestingly, the most significant factors influencing AS were the proteins IL23R (OR: 2.49), ATF6B (OR: 2.21), and C4A (OR: 1.38). These findings provide compelling information for further research on the role of these proteins in AS, warranting further investigation (TableĀ 1).
TableĀ 1
| id.exposure | b | se | P-val | or | or_lci95 | or_uci95 |
|---|---|---|---|---|---|---|
| IL23R | 0.910738095 | 0.17152 | 1.10E-07 | 2.486156877 | 1.776346799 | 3.479599828 |
| ATF6B | 0.790523956 | 0.100935112 | 4.80E-15 | 2.204551213 | 1.808849735 | 2.686815801 |
| C4A | 0.318389759 | 0.039770145 | 1.19E-15 | 1.374912042 | 1.271808972 | 1.486373476 |
| COL11A2 | 0.302283909 | 0.070992156 | 2.06E-05 | 1.352945285 | 1.177200641 | 1.554926901 |
| TNXB | 0.288305453 | 0.066304125 | 1.37E-05 | 1.334164767 | 1.171575435 | 1.519317981 |
| LILRB3 | 0.142045886 | 0.035405812 | 6.02E-05 | 1.152629536 | 1.075354628 | 1.235457414 |
| ERAP1 | 0.132335882 | 0.025460529 | 2.02E-07 | 1.141491661 | 1.085926181 | 1.199900357 |
| MICB | -0.361808092 | 0.049643729 | 3.14E-13 | 0.696416003 | 0.631845864 | 0.76758475 |
| CFB | -0.36645838 | 0.072386049 | 4.14E-07 | 0.693184987 | 0.601496215 | 0.79885029 |
| HLA-DQA2 | -0.450084251 | 0.046000788 | 1.32E-22 | 0.637574433 | 0.582605033 | 0.697730254 |
| AGER | -0.549864917 | 0.063904962 | 7.67E-18 | 0.577027752 | 0.509096017 | 0.654024026 |
| MICA | -0.596719252 | 0.024205555 | 3.49E-134 | 0.550615106 | 0.525102321 | 0.577367463 |
| MAPK14 | -0.906780645 | 0.183013878 | 7.24E-07 | 0.40382218 | 0.28210164 | 0.578062408 |
| AIF1 | -1.081463415 | 0.097452654 | 1.29E-28 | 0.33909892 | 0.280138651 | 0.410468449 |
| CLIC1 | -1.893118036 | 0.274137029 | 4.99E-12 | 0.150601495 | 0.087999283 | 0.257738581 |
| VARS1 | -2.370585134 | 0.297909331 | 1.76E-15 | 0.093426043 | 0.052105362 | 0.167514922 |
| HSPA1L | -2.424102426 | 0.304649057 | 1.76E-15 | 0.08855757 | 0.048741982 | 0.160897096 |
| MPIG6B | -3.59552822 | 0.92036903 | 9.36E-05 | 0.027446182 | 0.004519059 | 0.166692427 |
Causal plasma proteins in ankylosing spondylitis (AS).
Ankylosing spondylitis (AS), each identifier for the exposure factor being investigated, which in our study refers to specific plasma proteins (id.exposure), beta coefficient (b), standard error (se), P-value (P-val), lower confidence interval (lo_ci), upper confidence interval (up_ci), Odds Ratio (or), 95% confidence interval lower limit for odds ratio (or_lci95), 95% confidence interval upper limit for odds ratio (or_uci95).
Enrichment and construction of gene networks of drug targets
We conducted a Gene Ontology (GO) analysis on 18 shared protein targets, covering biological processes (BP), Molecular Function (MF) and Cellular Component (CC), as seen in FigureĀ 3A. Notable GO terms included positive regulation of interleukin-12 production (GO:0032735), regulation of T cell-mediated cytotoxicity (GO:0001914). The KEGG enrichment analysis showed that Th17 cell differentiation signaling pathway was significantly enriched in target proteins (see FigureĀ 3B). We also constructed a map showing interactions between these proteins, featuring 38 connection points and 82 connecting lines, which suggests a highly significant network based on a statistical measure (P-value:1.45e-12), as seen in FigureĀ 3C using the String platform.
FigureĀ 3
Colocalization analysis
In our research, we performed a detailed analysis to study how causal genetic variations and proteins were connected to AS. This technique, known as co-localization analysis, helps us understand which genetic changes are likely to influence the disease and its treatment. Specifically, we found that four proteinsāMAPK14, AIF1, ATF6B, and MICAā can serve as first-tier drug targets. HSPA1L and COL11A2 were second tiers, according to the results, while others were categorized as third-tier targets. Our findings suggested possible shared causal genetic variations between MAPK14 and AS (PPH4 = 0.977), while ATF6B could pose a risk factor for AS (PPH4 = 0.887). These results underscore our identification of several credible drug-related genes via MR and colocalization analysis, revealing a common genetic effect between target proteins and AS risk (TableĀ 2).
TableĀ 2
| Protein | N_SNPs | PPH0 | PPH1 | PPH2 | PPH3 | PPH4 |
|---|---|---|---|---|---|---|
| AGER | 3712 | 5.72E-127 | 0.0539114 | 7.44E-112 | 0.942793077 | 0.00329552 |
| AIF1 | 3856 | 5.32E-96 | 0.00167447 | 6.92E-74 | 0.102649734 | 0.8956758 |
| ATF6B | 5359 | 0 | 2.76E-06 | 0 | 0.112731838 | 0.8872654 |
| C4A | 6478 | 1.23E-87 | 0.12798836 | 1.60E-35 | 0.867830945 | 0.004180694 |
| CFB | 4550 | 0 | 5.65E-32 | 0 | 1 | 9.20E-63 |
| CLIC1 | 5123 | 4.51E-85 | 0.00515944 | 5.86E-58 | 0.994758254 | 8.23E-05 |
| COL11A2 | 4456 | 0 | 6.27E-06 | 0 | 0.264638428 | 0.7353553 |
| ERAP1 | 5769 | 1.66E-294 | 0.00557209 | 2.16E-175 | 0.994095938 | 0.000331968 |
| HLA-DQA2 | 5345 | 9.30E-103 | 0.01197295 | 1.21E-85 | 0.9835284 | 0.004498653 |
| HSPA1L | 5837 | 2.44E-57 | 0.00249477 | 3.17E-73 | 0.254142326 | 0.7433629 |
| IL23R | 4234 | 0 | 7.37E-79 | 0 | 1 | 3.22E-45 |
| LILRB3 | 5967 | 6.23E-134 | 0.06756285 | 8.10E-141 | 0.918001065 | 0.01443609 |
| MAPK14 | 4345 | 0 | 2.00E-07 | 0 | 0.022823 | 0.9771768 |
| MICA | 3487 | 6.32E-36 | 2.75E-05 | 8.22E-64 | 0.144419507 | 0.855553 |
| MICB | 6498 | 4.68E-63 | 0.13818637 | 6.08E-74 | 0.849662271 | 0.01215136 |
| MPIG6B | 4543 | 0 | 0.00280414 | 0 | 0.996948415 | 0.000247442 |
| TNXB | 5349 | 0 | 4.98E-09 | 0 | 0.735989895 | 0.2640101 |
| VARS1 | 4591 | 9.52E-48 | 0.86206095 | 1.24E-52 | 0.038984424 | 0.09895463 |
Results of the colocalization analysis.
Number of single nucleotide polymorphisms (nsnp),posterior probability of pypotheses (PPH),each identifier for the exposure factor being investigated, which in our study refers to specific plasma proteins (Protein).
Phenomewide MR analysis
We sourced data on gene-trait associations from the GWAS Catalog accessible at: https://gwas.mrcieu.ac.uk/. Our analysis focused on examining the link between gene variants and traits. We utilized cis-pQTLs to understand these relationships and conducted thorough searches to pinpoint studies that reported statistically significant genetic associations (P< 0.001) with specific traits. Our study incorporated a detailed PheWAS analysis to investigate how the top six proteins that colocalizeāHSPA1L, MICA, COL11A2, MAPK14, AIF1, and ATF6B were connected to We discovered that these proteins not only contribute to targeting AS but also significantly impact the development of other diseases. For example, AIF1, MICA, ATF6B, and HSPA1L were found to be associated with an increased risk of rheumatoid arthritis (RA), while AIF1 was also associated with an increased risk of atopic dermatitis. On the other hand, MAPK14, ATF6B, and COL11A2 were associated with a lower risk of both rheumatoid arthritis and primary sclerosing cholangitis (refer to Supplementary Table S2). exploration enables us to deepen our understanding of how specific genetic variations can influence disease mechanisms, providing critical insights for genetic research and biomedical applications beyond just treating AS.
Drug validation
Our research identified MAPK14 as a potential genetic drug target and biomarker in AS. By analyzing the DGIdb database, we discovered a link between MAPK14 and the drug pirfenidone, which is currently under clinical investigation. Interestingly, MAPK14 is also associated with three FDA-approved drugs: dasatinib, doxorubicin, and sorafenib. Although our study did not directly involve pharmaceutical action on AS, these findings provided new prospects for the treatment of AS and related diseases (Supplementary Table S3).
Molecular docking
In the realm of molecular docking (MD) investigations, the concept of binding energy serves as a fundamental metric for assessing ligand-receptor interactions. A binding energy less than 0 kcal/mol is indicative of a spontaneous binding process, confirming the thermodynamic feasibility of the ligand associating with the receptor. Specifically, a binding energy threshold of -7.2 kcal/mol is often utilized as a benchmark for strong molecular interactions, characterized by elevated affinity and specificity towards the receptor. In our analysis, we evaluated the docking profiles of pirfenidone, dasatinib, doxorubicin, and sorafenib with the kinase domain of MAPK14. The results demonstrated binding energies of -9.7 kcal/mol, -9.0 kcal/mol, -8.5 kcal/mol, and -12 kcal/mol, respectively. All values significantly surpass the -7.2 kcal/mol threshold, suggesting robust binding affinities (see FigureĀ 4, Supplementary Table S4 for details). Concurrently, we employed the methodology of molecular docking to validate the co-crystallized ligand with MAPK14 (Supplementary Figure S1). The RMSD (Root Mean Square Deviation) value between the co-crystal ligand and MAPK14 before and after docking is 0.321Ć , which is less than 2Ć , indicating that the molecular docking methodology has been validated. These findings imply a high potential for these compounds to inhibit MAPK14 activity effectively, which may be therapeutically beneficial in modulating pathways regulated by this kinase in AS (FigureĀ 5).
FigureĀ 4
FigureĀ 5
Discussion
To date, the treatment of ankylosing spondylitis (AS) continues to pose a considerable clinical challenge within the realm of medicine (). The discovery and development of innovative pharmaceuticals for AS are hindered by high costs and a limited number of approved therapeutic agents, which are often associated with severe adverse reactions or patient intolerance (). Recent advances in human genetics have led to the identification of pharmacological targets that are pertinent for AS treatment (). Some Food and Drug Administration (FDA) approved medications for AS-target immune system inflammation, such as tumor necrosis factor inhibitors and interleukin-17 inhibitors, to alleviate symptoms (). In this study, plasma proteomic data served as valuable resources for identifying potential drug targets. Using mendelian randomization (MR) analysis with matched AS-GWAS (Genome-wide association study) samples, we established causal relationships between genetic plasma proteomic variations associated with AS risk and the expression of specific proteins following the methods described in previous literature (). Simultaneously, the Phenome-wide Association Study (PheWAS) explores the connections between these proteins and a broad spectrum of phenotypic traits, enhancing our understanding of their roles across various medical conditions (). This approach increases the likelihood of successful drug development while reducing development costs. Ultimately, we identified 18 promising proteins for drug research, including AGER, AIF1, ATF6B, C4A, CFB, CLIC1, COL11A2, ERAP1, HLA-DQA2, HSPA1L, IL23R, LILRB3, MAPK14, MICA, MICB, MPIG6B, TNXB and VARS1. Among them, AIF1 and IL23R are associated with decreased risk of ankylosing spondylitis; MICA, MAPK14, and ATF6B are linked to increased risk of ankylosing spondylitis.
C4 and C4A, pivotal proteins within the human immune system, are encoded by distinct genes and categorized as C4 isotypes (47). They activate the complement pathway, crucial for pathogen clearance, and C4A is implicated in autoimmune disease risk due to its regulatory role in autoimmune responses (48). An in vitro studies suggest that AS pathogenesis is closely linked to complement activation, aligning with our findings (49).
Endoplasmic reticulum aminopeptidase 1 (ERAP1) plays a vital role in clarifying important biological pathways in AS pathogenesis, mainly linked to human leukocyte antigen B27 (HLA-B27) positive cases, by influencing peptides binding to class I molecules of the major histocompatibility complex (MHC) (50). ERAP1ās interaction with HLA-B27 influences the peptide processing crucial for disease susceptibility in AS. ERAP1 polymorphism correlates with AS severity and progression (51ā53). Research by Chen etĀ al. demonstrated that reducing ERAP1 levels decreases the surface presence of free HLA-B27 heavy chains (FHC) on antigen-presenting cells. This reduction lowers the activation of KIR3DL2, a critical immune receptor, consequently diminishing interleukin-2 (IL-2) production (54). These changes resulted in an expansion of Th17 cells and decreased IL-17A secretion in CD4+ T cells among patients with AS. The study suggested that the activity of ERAP1 determines the surface expression of HLA-B27 FHCs and may potentially facilitate the Th17 response through the interaction between HLA-B27 FHCs and KIR3DL2. Therefore, the activity of ERAP1 appears to be crucial in regulating the Th17 cell response and IL-2 production in AS. Our research work aligned with these results, suggesting that proteins C4A and ERAP1 may exert an influence on AS development by modulating the immune response, especially within the inflammatory pathways.
MAPK14 (mitogen-activated protein kinase 14), also known as p38 MAPK, plays a significant role in inflammation and immune response, linked to AS through gene polymorphisms near the MAPK14 locus (55, 56). Elevated gene expression levels of Myd88 (myeloid differentiation primary response 88), NF-kB (nuclear factor-kappa B) and MAPK14 in AS patients, compared to controls, were reported by Roozbehkia et al. (57). Although this work did not identify any FDA-approved therapeutics for AS that target MAPK14, molecular docking (MD) analysis was implemented to substantiate these findings. Our analysis utilized the Drug-Gene Interaction database (DGIdb) to ascertain pharmaceuticals associated with MAPK14, identifying pirfenidone, dasatinib, doxorubicin, and sorafenib. These agents demonstrated potent binding affinity to MAPK14, suggesting their potential efficacy in mitigating the enzymatic activity of MAPK14, thereby offering prospective therapeutic benefits in the management of AS. Pirfenidone, approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF), shows promising action on AS. Pirfenidone possesses anti-inflammatory and antifibrotic properties; its mechanisms include inhibition of TGF-β-induced fibroblast proliferation and suppression of inflammatory mediator production (58). Given the chronic inflammation and potential fibrosis in the pathological process of AS, including new bone formation (59), pirfenidone may have potential therapeutic utility in the treatment of AS. Due to the critical role of MAPK14 in regulating inflammation, inhibitors targeting this protein may lead to adverse effects, such as immunosuppression (60). Similarly, the immunomodulatory functions of activating transcription factor 6B (ATF6B), and AIF1 suggest that targeting these proteins could disrupt crucial immune processes, such as autophagy and apoptosis (61, 62). Future research will continue to assess these side effects and rigorously test them in preclinical studies to ensure patient safety.
In a summary, MAPK can be activated by various inflammatory cytokines, chemokines, and pattern recognition receptors, including IL-17, may affect cell proliferation, differentiation, and apoptosis in AS through cascades of signal transduction (63). The major histocompatibility complex class I (MHC) chain-related protein A (MICA) protein, which is activated in response to stress in natural killer (NK) cells, γΓ T cells, and other immune cells, binds to the NK receptor group 2 member D (NKG2D) receptor, triggering cytotoxicity and the release of inflammatory cytokines by NK cells and T cells. An imbalance in this pathway may increase the risk of AS (64). Unconventional HLA-B27 variants may trigger endoplasmic reticulum stress (ERS) through homodimerization, and ATF6B, a transmembrane protein with low transcriptional activity in the ER, may suppress ER stress activation and inflammation (65, 66). Allograft inflammatory factor 1 (AIF1), a calcium-binding protein, is involved in phagocytosis, membrane ruffling, and F-actin remodeling, and is associated with macrophage activation and various diseases (67). Research shows that knocking down Allograft Inflammatory Factor 1 (AIF1) suppresses antigen-specific CD4+ T cell proliferation, increases IL-10 production, and expands CD25+Foxp3+ regulatory T cell subsets, which inhibits inflammation (68). This observation is consistent with the results of our work. AIF1 might play a significant role in AS by regulating the differentiation and function of dendritic cells (Figure 5). Biological networks are complex, and it is postulated that in AS, MAPK14 and ATF6B may be interconnected through cellular and endoplasmic reticulum stress responses, while MICA and AIF1 may be associated with immune responses and inflammation.
Interleukin-12 (IL-12) may play a role in the pathogenesis of AS. Excessive IL-12 activity can trigger abnormal immune responses, potentially contributing to the development and worsening of AS (69). IL-12/23 monoclonal antibody (Ustekinumab) is currently approved to treat AS to alleviate symptoms (70). More research is needed to clarify the exact role of IL-12 in the pathogenic mechanisms of AS.
Recent studies highlight Th17 cellsā adaptive gene expression, influencing their pathogenic potential in AS (71, 72). These cells, which can co-express RORγt and TBX21, are implicated in autoimmune pathologies, while others produce cytokines targeting specific pathogens (73, 74). Elevated Th17 activity correlates with increased inflammatory cytokine production, contributing to bone damage in AS (75). IL23R polymorphisms also relate to disease susceptibility, influencing IL-17 production (76ā78). Our findings support the development of multitarget drugs to inhibit Th17 differentiation and reduce pro-inflammatory cytokine production as a therapeutic strategy for AS.
This study identified genetic associations between circulating proteins and AS using large-scale MR analysis, revealing novel pathways in AS pathogenesis. The results were robust, adhering to stringent instrumental variable criteria. Additionally, a PheWAS analysis assessed the safety of these proteins as drug targets, aiming to mitigate severe side effects.
However, limitations exist. The proteins studied were derived from whole blood and may not reflect tissue-specific processes in AS. Moreover, the magnetic resonance approach presumes uniform drug efficacy across individuals, which contrasts with variable clinical responses. The findings predominantly involve European populations, highlighting the need for more diverse studies to enhance generalizability and understand protein-specific mechanisms in AS. Due to limitations, in vitro and in vivo experiments may be constrained. We plan to include them in future research or engage in multicenter laboratory collaboration.
In conclusion, this research highlights the utility of MR in identifying potential drug targets or biomarkers for AS, implicating proteins involved in Th17 differentiation in AS pathogenesis. These proteins could serve as early screening tools or therapeutic targets. Future research is necessary to confirm these potential applications.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Ethics statement
All the studies involved to complement this study were approved by relevant ethics committees. All participants had provided the written informed consent in these original studies respectively. for the studies involving humans because All the studies involved to complement this study were approved by relevant ethics committees. All participants had provided the written informed consent in these original studies respectively. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
YZ: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing ā original draft, Writing ā review & editing. WL: Conceptualization, Investigation, Methodology, Project administration, Resources, Supervision, Writing ā review & editing. JL: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Resources, Writing ā original draft. HZ: Writing ā review & editing, Writing ā original draft, Resources, Methodology, Investigation, Formal Analysis, Data curation.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was financially supported in part by research grants from the Shenzhen Science and Technology Project (JCYJ20210324111805014). Scientific research project of the Guangdong Provincial Bureau of Traditional Chinese Medicine Project (20221343) with Ye Zhang.
Acknowledgments
We thank Shanghai Oebiotech Co., Ltd. (https://cloud.oebiotech.cn/, last accessed on 12 January 2024) for providing data analysis and visualization support. We thank the skilled support for figures provided by Figdraw (www.figdraw.com, last accessed on 26 April 2024). We appreciate the insights provided by Shuai Chen for helping with the pattern design.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1394438/full#supplementary-material
Supplementary FigureĀ 1Molecular docking Analysis of MAPK14 protein with a co-crystal ligand. The left panel shows the overall structure of the MAPK14 protein. The right panel illustrates the specific interactions between the co-crystal ligand and key amino acid residues in the MAPK14 protein. The panel represents the protein in a ribbon diagram, with the ligand depicted in a stick model, focusing on the binding site. The yellow dashed lines represent potential hydrogen bond contacts with key amino acids, with distances given in angstroms. quantitative trait loci (pQTLs), Instrumental variables (IVs), single nucleotide polymorphism (SNP), linkage disequilibrium (LD), mendelian randomization (MR), Wald ratio (WR), ankylosing spondylitis (AS), gene ontology (GO), Kyoto encyclopedia of genes and genomes (KEGG), Drug gene interaction database (DGIdb), Phenome-wide association study (PheWAS),Molecular docking (MD), major histocompatibility complex class I (MHC) chain-related protein A (MICA), mitogen-activated protein kinase 14 (MAPK14), activating transcription factor 6B (ATF6B), Allograft inflammatory factor 1 (AIF1), NK receptor group 2 member D (NKG2D), natural killer (NK), Apoptosis-associated speck-like protein containing a CARD (Act1), endoplasmic reticulum (ER), human leukocyte antigen B27 (HLA-B27), dendritic cells (DCs), regulatory T cells (Tregs), Macrophages (MĆ), Interleukin 17 (IL-17), Interleukin 23 (IL-23), Interleukin 10 (IL-10), T-helper (Th) cells, Forkhead box protein P (FoxP), Antigen presenting cell (APC).
References
1
YangHChenYXuWShaoMDengJXuSet al. Epigenetics of ankylosing spondylitis: Recent developments. Int J Rheum Dis. (2021) 24:487ā93. doi:Ā 10.1111/1756ā185X.14080
2
KwonSRKimTHKimTJParkWShimSC. The epidemiology and treatment of ankylosing spondylitis in Korea. J Rheum Dis. (2022) 29:193ā9. doi:Ā 10.4078/jrd.22.0023
3
JungSMKimWU. Targeted immunotherapy for autoimmune disease. Immune Netw. (2022) 22:e9. doi:Ā 10.4110/in.2022.22.e9
4
WardMMDeodharAGenslerLSDubreuilMYuDKhanMAet al. 2019 Update of the American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). (2019) 71:1285ā99. doi:Ā 10.1002/acr.24025
5
BerdigaliyevNAljofanM. An overview of drug discovery and development. Future Med Chem. (2020) 12:939ā47. doi:Ā 10.4155/fmc-2019ā0307
6
JinMLiuPQiG. Exploring potential biomarkers of early thymoma based on serum proteomics. Protein Pept Lett. (2023) 31:74ā83. doi:Ā 10.2174/0109298665275655231103105924
7
WuJTangBTangY. Allele-specific genome targeting in the development of precision medicine. Theranostics. (2020) 10:3118ā37. doi:Ā 10.7150/thno.43298
8
CarssKJDeatonAMDel Rio-EspinolaADiogoDFieldenMKulkarniDAet al. Using human genetics to improve safety assessment of therapeutics. Nat Rev Drug Discovery. (2023) 22:145ā62. doi:Ā 10.1038/s41573ā022-00561-w
9
ChauquetSZhuZOāDonovanMCWaltersJTRWrayNRShahS. Association of antihypertensive drug target genes with psychiatric disorders: A Mendelian randomization study. JAMA Psychiatry. (2021) 78:623ā31. doi:Ā 10.1001/jamapsychiatry.2021.0005
10
BakkerMKvan StratenTChongMParĆ©GGillDRuigrokYM. Anti-epileptic drug target perturbation and intracranial aneurysm risk: Mendelian randomization and colocalization study. Stroke. (2023) 54:208ā16. doi:Ā 10.1161/STROKEAHA.122.040598
11
YangCFariasFHGIbanezLSuhyASadlerBFernandezMVet al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat Neurosci. (2021) 24:1302ā12. doi:Ā 10.1038/s41593ā021-00886ā6
12
SunBBMaranvilleJCPetersJEStaceyDStaleyJRBlackshawJet al. Genomic atlas of the human plasma proteome. Nature. (2018) 558:73ā9. doi:Ā 10.1038/s41586ā018-0175ā2
13
SuhreKArnoldMBhagwatAMCottonRJEngelkeRRafflerJet al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. (2017) 8:14357. doi:Ā 10.1038/ncomms14357
14
FolkersenLFaumanESabater-LlealMStrawbridgeRJFrÄnbergMSennbladBet al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PloS Genet. (2017) 13:e1006706. doi: 10.1371/journal.pgen.1006706
15
YaoCChenGSongCKeefeJMendelsonMHuanTet al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun. (2018) 9:3268. doi:Ā 10.1038/s41467ā018-05512-x
16
EmilssonVIlkovMLambJRFinkelNGudmundssonEFPittsRet al. Co-regulatory networks of human serum proteins link genetics to disease. Science. (2018) 361:769ā73. doi:Ā 10.1126/science.aaq1327
17
ZhengJHaberlandVBairdDWalkerVHaycockPCHurleMRet al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. (2020) 52:1122ā31. doi:Ā 10.1038/s41588ā020-0682ā6
18
YangMSuYXuKWanXXieJLiuLet al. Iron, copper, zinc and magnesium on rheumatoid arthritis: a two-sample Mendelian randomization study. Int J Environ Health Res. (2023) 30:1ā14. doi:Ā 10.1080/09603123.2023.2274377
19
BottigliengoDFocoLSeiblerPKleinCKƶnigIRDel GrecoMF. A Mendelian randomization study investigating the causal role of inflammation on Parkinsonās disease. Brain. (2022) 145:3444ā53. doi:Ā 10.1093/brain/awac193
20
GudichaDWSchmittmannVDVermuntJK. Statistical power of likelihood ratio and Wald tests in latent class models with covariates. Behav Res Methods. (2017) 49:1824ā37. doi:Ā 10.3758/s13428ā016-0825-y
21
FridleyBLIversenETsaiYYJenkinsGDGoodeELSellersTA. A latent model for prioritization of SNPs for functional studies. PloS One. (2011) 6:e20764. doi:Ā 10.1371/journal.pone.0020764
22
ArmstrongRA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. (2014) 34:502ā8. doi:Ā 10.1111/opo.12131
23
TangDChenMHuangXZhangGZengLZhangGet al. SRplot: A free online platform for data visualization and graphing. PloS One. (2023) 18:e0294236. doi:Ā 10.1371/journal.pone.0294236
24
BurgessSSmallDSThompsonSG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. (2017) 26:2333ā55. doi:Ā 10.1177/0962280215597579
25
HukkuAPividoriMLucaFPique-RegiRImHKWenX. Probabilistic colocalization of genetic variants from complex and molecular traits: promise and limitations. Am J Hum Genet. (2021) 108:25ā35. doi:Ā 10.1016/j.ajhg.2020.11.012
26
SuJZhouWYuanHWangHZhangH. Identification and functional analysis of novel biomarkers in adenoid cystic carcinoma. Cell Mol Biol (Noisy-le-grand). (2023) 69:203ā7. doi:Ā 10.14715/cmb/2023.69.6.31
27
LinJZhouJXuY. Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain. (2023) 146:3364ā72. doi:Ā 10.1093/brain/awad070
28
ChenYLiCChengSPanCZhangHZhangJet al. The causal relationships between sleep-related phenotypes and body composition: A Mendelian randomized study. J Clin Endocrinol Metab. (2022) 107:e3463ā73. doi:Ā 10.1210/clinem/dgac234
29
YangRChenHXingLWangBHuMOuXet al. Hypoxia-induced circWSB1 promotes breast cancer progression through destabilizing p53 by interacting with USP10. Mol Cancer. (2022) 21:88. doi:Ā 10.1186/s12943ā022-01567-z
30
YuanSSunJLuYXuFLiDJiangFet al. Health effects of milk consumption: phenome-wide Mendelian randomization study. BMC Med. (2022) 20:455. doi:Ā 10.1186/s12916ā022-02658-w
31
LiuXTianDLiCTangBWangZZhangRet al. GWAS Atlas: an updated knowledgebase integrating more curated associations in plants and animals. Nucleic Acids Res. (2023) 51:D969ā76. doi:Ā 10.1093/nar/gkac924
32
KamatMABlackshawJAYoungRSurendranPBurgessSDaneshJet al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. (2019) 35:4851ā3. doi:Ā 10.1093/bioinformatics/btz469
33
FreshourSLKiwalaSCottoKCCoffmanACMcMichaelJFSongJJet al. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. (2021) 49:D1144ā51. doi:Ā 10.1093/nar/gkaa1084
34
WangJKangZLiuYLiZLiuYLiuJ. Identification of immune cell infiltration and diagnostic biomarkers in unstable atherosclerotic plaques by integrated bioinformatics analysis and machine learning. Front Immunol. (2022) 13:956078. doi:Ā 10.3389/fimmu.2022.956078
35
PrestegardJH. A perspective on the PDBās impact on the field of glycobiology. J Biol Chem. (2021) 296:100556. doi:Ā 10.1016/j.jbc.2021.100556
36
SeeligerDde GrootBL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. (2010) 24:417ā22. doi:Ā 10.1007/s10822ā010-9352ā6
37
WangYXiaoJSuzekTOZhangJWangJZhouZet al. PubChemās bioAssay database. Nucleic Acids Res. (2012) 40:D400ā12. doi:Ā 10.1093/nar/gkr1132
38
OāBoyleNMMorleyCHutchisonGR. Pybel: a Python wrapper for the OpenBabel cheminformatics toolkit. Chem Cent J. (2008) 2:5. doi:Ā 10.1186/1752ā153X-2ā5
39
HariniMKavithaKPrabakaranVKrithikaADineshSRajalakshmiAet al. Identification of apigenin-4ā-glucoside as bacterial DNA gyrase inhibitor by QSAR modeling, molecular docking, DFT, molecular dynamics, and in vitro confirmation studies. J Mol Model. (2024) 30:22. doi:Ā 10.1007/s00894ā023-05813-z
40
GovenderNZulkifliNSBadrul HishamNFAb GhaniNSMohamed-HusseinZA. Pea eggplant (Solanum torvum Swartz) is a source of plant food polyphenols with SARS-CoV inhibiting potential. PeerJ. (2022) 10:e14168. doi:Ā 10.7717/peerj.14168
41
FattoriniFGentileschiSCigoliniCTerenziRPataAPEstiLet al. Axial spondyloarthritis: one year in review 2023. Clin Exp Rheumatol. (2023) 41:2142ā50. doi:Ā 10.55563/clinexprheumatol/9fhz98
42
DrososAAVenetsanopoulouAIVoulgariPV. Axial Spondyloarthritis: Evolving concepts regarding the diseaseās diagnosis and treatment. Eur J Intern Med. (2023) 117:21ā7. doi:Ā 10.1016/j.ejim.2023.06.026
43
KenyonMMaguireSRueda PujolAOāSheaFMcManusR. The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease. Rheumatol Int. (2022) 42:2085ā95. doi:Ā 10.1007/s00296ā022-05174ā5
44
ChenYLiuSGongWGuoPXueFZhouXet al. Protein-centric omics integration analysis identifies candidate plasma proteins for multiple autoimmune diseases. Hum Genet. (2023). doi:Ā 10.1007/s00439ā023-02627ā0
45
GuiJMengLHuangDWangLYangXDingRet al. Identification of novel proteins for sleep apnea by integrating genome-wide association data and human brain proteomes. Sleep Med. (2023) 114:92ā9. doi:Ā 10.1016/j.sleep.2023.12.026
46
SchifferliJAPaccaudJP. Two isotypes of human C4, C4A and C4B have different structure and function. Complement Inflamm. (1989) 6:19ā26. doi:Ā 10.1159/000463068
47
CossSLZhouDChuaGTAzizRAHoffmanRPWuYLet al. The complement system and human autoimmune diseases. J Autoimmun. (2023) 137:102979. doi:Ā 10.1016/j.jaut.2022.102979
48
YangCDingPWangQZhangLZhangXZhaoJet al. Inhibition of complement retards ankylosing spondylitis progression. Sci Rep. (2016) 6:34643. doi:Ā 10.1038/srep34643
49
FaticaMDāAntonioANovelliLTriggianesePConigliaroPGrecoEet al. How has molecular biology enhanced our undertaking of axSpA and its management. Curr Rheumatol Rep. (2023) 25:12ā33. doi:Ā 10.1007/s11926ā022-01092ā4
50
SaadMAAbdul-SattarABAbdelalITBarakaA. Shedding light on the role of ERAP1 in axial spondyloarthritis. Cureus. (2023) 15:e48806. doi:Ā 10.7759/cureus.48806
51
EvansDMSpencerCCPointonJJSuZHarveyDKochanGet al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. (2011) 43:761ā7. doi:Ā 10.1038/ng.873
52
KüçükÅahinOAteÅATürkƧaparNTƶrünerMTurgayMDumanTet al. Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey. Turk J Gastroenterol. (2016) 27:317ā24. doi:Ā 10.5152/tjg.2016.15466
53
ChenRYaoLMengTXuW. The association between seven ERAP1 polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis involving 8,530 cases and 12,449 controls. Rheumatol Int. (2012) 32:909ā14. doi:Ā 10.1007/s00296ā010-1712-y
54
ChenLRidleyAHammitzschAAl-MossawiMHBuntingHGeorgiadisDet al. Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis. Ann Rheum Dis. (2016) 75:916ā23. doi:Ā 10.1136/annrheumdis-2014ā206996
55
BonneyEA. Mapping out p38MAPK. Am J Reprod Immunol. (2017) 77:10. doi:Ā 10.1111/aji.12652
56
CostantinoFTalpinASaid-NahalRLeboimeAZinovievaEZelenikaDet al. A family-based genome-wide association study reveals an association of spondyloarthritis with MAPK14. Ann Rheum Dis. (2017) 76:310ā4. doi:Ā 10.1136/annrheumdis-2016ā209449
57
RoozbehkiaMMahmoudiMAletahaSRezaeiNFattahiMJJafarnezhad-AnsarihaFet al. The potent suppressive effect of β-d-mannuronic acid (M2000) on molecular expression of the TLR/NF-kB Signaling Pathway in ankylosing spondylitis patients. Int Immunopharmacol. (2017) 52:191ā6. doi:Ā 10.1016/j.intimp.2017.08.018
58
ManRKGogikarANandaAJangaLSNSambeHGYasirMet al. A comparison of the effectiveness of nintedanib and pirfenidone in treating idiopathic pulmonary fibrosis: A systematic review. Cureus. (2024) 16:e54268. doi:Ā 10.7759/cureus.54268
59
LiuZCaiMKeHDengHYeWWangTet al. Fibroblast insights into the pathogenesis of ankylosing spondylitis. J Inflammation Res. (2023) 16:6301ā17. doi:Ā 10.2147/JIR.S439604
60
LoUSelvarajVPlaneJMChechnevaOVOtsuKDengW. p38α (MAPK14) critically regulates the immunological response and the production of specific cytokines and chemokines in astrocytes. Sci Rep. (2014) 4:7405. doi: 10.1038/srep07405
61
ZhaoYYYanDJChenZW. Role of AIF-1 in the regulation of inflammatory activation and diverse disease processes. Cell Immunol. (2013) 284:75ā83. doi:Ā 10.1016/j.cellimm.2013.07.008
62
RozpedekWNowakAPytelDDiehlJAMajsterekI. Molecular basis of human diseases and targeted therapy based on small-molecule inhibitors of ER stress-induced signaling pathways. Curr Mol Med. (2017) 17:118ā32. doi:Ā 10.2174/1566524017666170306122643
63
ArthurJSLeySC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. (2013) 13:679ā92. doi:Ā 10.1038/nri3495
64
FernĆ”ndez-TorresJZamudio-CuevasYRuiz-DĆ”vilaXLópez-MacayAMartĆnez-FloresK. MICA and NLRP3 gene polymorphisms interact synergistically affecting the risk of ankylosing spondylitis. Immunol Res. (2024) 72:119ā27. doi:Ā 10.1007/s12026ā023-09419ā8
65
GuilianoDBFussellHLenartITsaoENesbethDFletcherAJet al. Endoplasmic reticulum degradation-enhancing α-mannosidase-like protein 1 targets misfolded HLA-B27 dimers for endoplasmic reticulum-associated degradation. Arthritis Rheumatol. (2014) 66:2976ā88. doi:Ā 10.1002/art.38809
66
ForouhanMMoriKBoot-HandfordRP. Paradoxical roles of ATF6α and ATF6β in modulating disease severity caused by mutations in collagen X. Matrix Biol. (2018) 70:50ā71. doi:Ā 10.1016/j.matbio.2018.03.004
67
De Leon-OlivaDGarcia-MonteroCFraile-MartinezOBoaruDLGarcĆa-PuenteLRios-ParraAet al. AIF1: function and connection with inflammatory diseases. Biol (Basel). (2023) 12:694. doi:Ā 10.3390/biology12050694
68
ElizondoDMAndargieTEYangDKacsintaADLipscombMW. Inhibition of allograft inflammatory factor-1 in dendritic cells restrains CD4+ T cell effector responses and induces CD25+Foxp3+ T regulatory subsets. Front Immunol. (2017) 8:1502. doi:Ā 10.3389/fimmu.2017.01502
69
FiehnC. Biologikatherapie von rheumatoider Arthritis und Spondyloarthritiden [Treatment of rheumatoid arthritis and spondylarthritis with biologics]. Internist (Berl). (2022) 63:135ā42. doi:Ā 10.1007/s00108ā021-01248-x
70
TahirH. Therapies in ankylosing spondylitis-from clinical trials to clinical practice. Rheumatol (Oxford). (2018) 57:vi23ā8. doi:Ā 10.1093/rheumatology/key152
71
ShiYWeiBLiLWangBSunM. Th17 cells and inflammation in neurological disorders: Possible mechanisms of action. Front Immunol. (2022) 13:932152. doi:Ā 10.3389/fimmu.2022.932152
72
SimoneDStingoACicciaF. Genetic and environmental determinants of T helper 17 pathogenicity in spondyloarthropathies. Front Genet. (2021) 12:703242. doi:Ā 10.3389/fgene.2021.703242
73
ZengJLiMZhaoQChenMZhaoLWeiSet al. Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases. J Pharm Anal. (2023) 13:545ā62. doi:Ā 10.1016/j.jpha.2023.05.009
74
ZielinskiCEMeleFAschenbrennerDJarrossayDRonchiFGattornoMet al. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature. (2012) 484:514ā8. doi:Ā 10.1038/nature10957
75
ZhuWHeXChengKZhangLChenDWangXet al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. (2019) 7:22. doi:Ā 10.1038/s41413ā019-0057ā8
76
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. (2007) 447:661ā78. doi:Ā 10.1038/nature05911
77
VecellioMCohenCJRobertsARWordsworthPBKennaTJ. RUNX3 and T-bet in immunopathogenesis of ankylosing spondylitis-novel targets for therapy? Front Immunol. (2019) 9:3132. doi:Ā 10.3389/fimmu.2018.03132
78
AbdollahiETavasolianFMomtazi-BorojeniAASamadiMRafatpanahH. Protective role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated diseases: A comprehensive review. J Immunotoxicol. (2016) 13:286ā300. doi:Ā 10.3109/1547691X.2015.1115448
Summary
Keywords
Ankylosing spondylitis, mendelian randomization, drug target, biomarker, colocalization, Phenomewide Association Study, (PheWAS), proteomics
Citation
Zhang Y, Liu W, Lai J and Zeng H (2024) Genetic associations in ankylosing spondylitis: circulating proteins as drug targets and biomarkers. Front. Immunol. 15:1394438. doi: 10.3389/fimmu.2024.1394438
Received
01 March 2024
Accepted
29 April 2024
Published
21 May 2024
Volume
15 - 2024
Edited by
Abdullah A. Elgazar, Kafrelsheikh University, Egypt
Reviewed by
Shimaa Abass, Kafrelsheikh University, Egypt
Marwa Balaha, Kafrelsheikh University, Egypt
Updates
Copyright
Ā© 2024 Zhang, Liu, Lai and Zeng.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Huiqiong Zeng, 15986686048@139.com
ā These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.